Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod Adjunctive to Endovascular Treatment for Large Vessel Occlusion Stroke (FATE-ET)
ChiCTR2600129021Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in brain infarction comparing Fingolimod + endovascular treatment with Placebo + endovascular treatment (2 arms). Primary endpoints: Modified Rankin Scale score at 90 days and Death within 90 days (any cause). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
fingolimod
03
Conditions
brain infarction
Beyond the preview
Go deeper on ChiCTR2600129021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129021.